VivoSeq
Oncology

Metastatic Castration-Resistant Prostate Carcinoma

6

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Metastatic Castration-Resistant Prostate Carcinoma is an early-stage landscape with 6 programs across 4 companies. The most active players are EMD Serono, Merck & Co., Astellas.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

PreclinicalMerck & Co. logo

Merck & Co.

1 program

PreclinicalAstellas logo

Astellas

1 program

PreclinicalSanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody120%Cell therapy120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Not yet recruiting1 · 20%
Suspended1 · 20%

Clinical Trials

Trial Activity

A Phase 2 Study of Biomarker-Modulated PSMA Theranostics
Recruiting·UUniversity of Washington·Phase 2·NCT06526299·51 enrolled
A Phase 1 Study to Investigate Safety of Escalating Cycle 1 Dose of Lu-177-PSMA-617 Radioligand Therapy (RLT) in Metastatic Castration Resistant Prostate Cancer (mCRPC): The ESCENDO Trial
Not yet recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT07682649·20 enrolled
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT07200830·1,524 enrolled
Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC
Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT06236139·48 enrolled
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Suspended·National Cancer Institute (NCI)·Preclinical·NCT04071236·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)